Who Should Consider GLP-1 and What Providers Should Evaluate First GLP-1 therapy may be appropriate for men with BMI 30, or 27 with weight-related comorbidities (hypertension, type 2 diabetes, dyslipidemia), and who have attempted lifestyle modification
Ongoing trials aim to clarify: Cardiovascular safety Long-term weight durability Role in prediabetes and non-diabetic populations Comparison to semaglutide and tirzepatide Until then, we continue to emphasize current best practices: lifestyle support, personalized nutrition, advanced lipid testing, and thoughtful pharmacotherapy
GLP-1 receptor agonist injections like Semaglutide and Tirzepatide are offering life-changing weight loss for many women struggling with PCOS-related weight gain
With insurance, you might only need to pay a copay, potentially as low as $0
10.1155/2019/7861297 106 WangX.ChenX.TangY.WuJ.QinD.YuL.et al (2022a)
Researchers at the University of Oxford found that beta-arrestin mediated desensitization in pancreatic beta cells recovered within six hours of agonist removal
